| INTRODUCTION
The Gut and Obesity Asia (GO ASIA) Workgroup was formed in November 2014 under the auspices of the Asian Pacific Association of Gastroenterology with the expressed aim of establishing a consortium to study the relationships between obesity and gastrointestinal diseases, and to guide future research in the Asia Pacific region. 1 During a meeting at the Asia Pacific Digestive Week 2015, nonalcoholic fatty liver disease (NAFLD) was identified as one of the key focus areas. The prevalence of NAFLD is on the rise due to the increasing prevalence of obesity, and the disease is estimated to affect up to 30% of the general population in the Asia Pacific region. 2 In a large population-based study using proton-magnetic resonance spectroscopy in Hong Kong, the prevalence of NAFLD was found to be 27.3%. 3 Several large population-based studies clearly demonstrated the increasing prevalence of NAFLD along with the increasing prevalence of obesity in Asia. 4 In China, for example, the prevalence of obe- On average, Asian NAFLD patients also have less severe histological features. 8 Therefore, it is important to provide high quality regionwide data from Asia. Nonalcoholic steatohepatitis (NASH), the more severe form of NAFLD, can lead to cirrhosis and is associated with increased risk of liver-related complications and mortality, especially in the presence of advanced fibrosis. 9 The diagnosis of NASH is based on histopathological examination of a liver biopsy specimen. Because a liver biopsy is invasive and seldom performed for NAFLD patients in routine clinical practice, studies on NAFLD based on histological data often consisted of relatively small number of patients. [10] [11] [12] [13] The disparity in socio-economic development in the different Asian countries may also influence healthcare resource utilisation, including the investigation and treatment of diseases such as NAFLD. The aims of the current study were to look at the factors associated with NASH and advanced fibrosis, and the medical treatment of NAFLD patients across centres, using the GO ASIA Workgroup as the platform.
2 | ME TH ODS
| Participating centres and cases
We included centres in the GO ASIA Workgroup which were able to provide at least 30 cases of biopsy-proven NAFLD. Ethical approval was obtained from each of the participating centres prior to the commencement of the study. 
| Histological data
Histopathological findings were reported according to the nonalcoholic steatohepatitis clinical research network scoring system across all the centres to ensure uniformity. 17 The slides were reviewed again and graded accordingly by the histopathologist of the respective centres if a different scoring system was used previously. NASH was defined as the presence of significant hepatic steatosis (>5% of hepatocytes), lobular inflammation and hepatocyte ballooning (≥ grade 1 for each) with or without fibrosis. Fibrosis stages 3 and 4
were considered as advanced fibrosis. Patients were further divided into four histological subgroups for further analyses as follows: nonalcoholic fatty liver (NAFL), NASH without advanced fibrosis, NASH with advanced fibrosis, and advanced fibrosis without NASH (also known as "burned-out" NASH). As the study only included cases with significant hepatic steatosis, patients with "burned-out" NASH who may no longer have significant hepatic steatosis were excluded.
Investigators from each of the centres were asked to provide the indications for liver biopsy at their centre and the proportion of patients for each of the indications.
| Statistical analysis
Data were analysed using SPSS 16.0 (SPSS Inc., Chicago, Illinois, US). 
| Indications for liver biopsy
The indications for liver biopsy for the different centres are summarised in Table S2 (available online).
| Histological severity
The percentage of biopsy-proven NAFLD patients with NASH and advanced fibrosis was 62.9% and 17.2%, respectively, in the overall study population. The percentage of patients with NASH from the different countries is as shown in Figure 2 . The percentage of patients with NASH was particularly high in the Singaporean and Japanese cohorts at 97.4%, and 93.8%, respectively. In the other countries, the percentage of patients with NASH ranged from 46.1% to 71.1%. The percentage of patients with advanced fibrosis from the different countries is as shown in Figure 3 . The percentage of patients with advanced fibrosis was highest in the Singaporean cohort at 31.6%. In other countries, the percentage of patients with advanced fibrosis ranged from 7.7% to 25.0%. Interestingly, the Japanese cohort had one of the lowest percentages of patients with advanced fibrosis despite having one of the highest percentages of patients with NASH. This discrepancy in NASH and advanced fibrosis was due to the Japanese bariatric cohort which did not have any patients with advanced fibrosis despite the high prevalence of NASH.
3.5 | Development of risk score for NASH and for advanced fibrosis
Patients were randomly assigned into a training cohort (n = 483) and a validation cohort (n = 525). Patients in the training cohort were younger and had higher BMI but were less likely to have hypertension compared with the validation cohort. They also had lower ASTto-ALT ratio, fasting blood sugar and HbA1c levels but higher LDL and platelet levels ( (Table S4) . Points were assigned to each of the factors according to its adjusted OR on multivariate analysis. The adjusted OR was halved and then rounded to the nearest whole number. The sum of points in an individual patient forms the Asia-Pacific NASH risk score (Table 2 ). The score was arbitrarily divided into three tiers of risk:
score 0-1, low risk; score 2-3, moderate risk; score 4-6, high risk.
The number of patients and the percentage of patients with NASH in each of the risk groups are comparable in the training and validation cohorts (Table 3 ). The sensitivity, specificity, positive predictive value and negative predictive value of the score for NASH in the training cohort was 87%, 61%, 83% and 68%, respectively, while in the validation cohort was 76%, 67%, 80% and 61%, respectively.
The sensitivity, specificity, positive predictive value and negative predictive value were computed based on patients with low and high risk scores while patients with moderate risk score were considered indeterminate.
In the training cohort, patients with advanced fibrosis were older, more likely to have diabetes mellitus and hypertension, and had higher GGT, FBS and HbA1c levels, and lower TC, LDL and platelet levels (Table S5) . On multivariate analysis, independent factors associated with advanced fibrosis were age ≥ 55 years old (OR = 4.693, 95% CI = 2.746-8.018, P < 0.001, diabetes mellitus (OR = 2.046, 95% CI = 1.148-3.649, P = 0.015) and platelet count < 150 9 10 9 /L (OR = 2.572, 95% CI = 1.072-6.169, P = 0.034 (Table S6) (Table 5 ). The sensitivity, specificity, positive predictive value and negative predictive value of the score for advanced fibrosis in the training cohort was 82%, 74%, 39% and 95%, respectively, while in the validation cohort was 89%, 63%, 38% and 96%, respectively. The sensitivity, specificity, positive predictive value and negative predictive value were computed based on patients with low and high risk scores while patients with moderate risk score were considered indeterminate.
| Characteristics of patients according to histological subgroups
Among patients with NASH, those with advanced fibrosis were older, had lower BMI and more likely to have central obesity, diabetes mellitus and hypertension but less likely to have dyslipidaemia.
NASH patients with advanced fibrosis had significantly higher serum AST, GGT, FBS and HbA1c levels, and lower serum TC, LDL and platelet levels (Table S7) . Independent factors associated with advanced fibrosis in patients with NASH were older age (OR = 1.053, 95% (Table S8 ). Among patients with advanced fibrosis, those with NASH were more likely to have dyslipidaemia and had higher serum ALT, AST and GGT levels (Table S7) . Independent factors associated with NASH among patients with advanced fibrosis was a higher serum GGT level (OR = 1.029, 95% CI = 1.009-1.050, P = 0.005) (Table S9 ). Serum GGT level is fair for diagnosis of NASH among patients with advanced fibrosis with an AUROC of 0.78. The optimal cut-off was 60 U/L with sensitivity, specificity, positive predictive value, negative predictive value of 74%, 72%, 89% and 48%, respectively. Among patients without NASH, those with advanced fibrosis were older, more likely to have diabetes mellitus and hypertension, had higher serum FBS and HbA1c levels and lower serum albumin, TC, LDL and platelet levels (Table S7) . Independent factors associated with advanced fibrosis among patients without NASH were obesity (OR = 3.900, 95% CI = 1.070-14.21, P = 0.039) and diabetes mellitus (OR = 5.068, 95% CI = 1.629-15.77, P = 0.005) (Table S10) .
Independent factors discriminating each of the histological subgroups are summarised in Figure 4 .
| Medical treatment of NAFLD
Data on medical treatment was available for 673 patients from five centres ( Table 6 ). There were missing data for 56 patients in the training cohort and 72 patients in the validation cohort that precluded calculation of this risk score for the patients. There were missing data for five patients in the training cohort and two patients in the validation cohort that precluded calculation of this risk score for the patients. On subgroup analysis, higher serum GGT level was identified as an independent factor associated with NASH in patients with advanced fibrosis. As simple and reliable noninvasive test for advanced liver fibrosis is becoming more widely available, 20 serum GGT level may be useful to further identify patients with advanced fibrosis who are likely to have NASH to receive specific treatment to mitigate disease progression. In addition, we identified a small group of NAFLD patients who have advanced fibrosis but not NASH, also known as "burned-out" NASH, and compared the characteristics of these patients with those who have NAFL without advanced fibrosis. Whether these patients have increased risk of adverse outcomes compared with patients with NASH and advanced fibrosis deserves further studies.
Structured lifestyle intervention has been shown to be effective in leading to NASH resolution and even regression of liver fibrosis. 21 However, only minority of the patients in this study were referred for structured lifestyle intervention. This may be because of the lack of structured lifestyle programs that catered specifically for NAFLD patients in the centres. Moreover, structured lifestyle intervention requires a high level of commitment from patients, and only a small proportion of patients could achieve the desired weight loss even in the best setting of a clinical trial. For example, only 10% of biopsy-proven NASH patients in a 12-month comprehensive lifestyle program were able to lose ≥ 10% of their baseline weight while the majority (70%) had < 5% weight loss, and 21% of the latter group had fibrosis progression. 21 The use of medical treatment for diabetes mellitus for the Japanese nonbariatric cohort and the use of medical treatment for hypertension and dyslipidaemia for the Korean cohort were relatively low despite the prevalence of these comorbidities being similar to cohorts from other countries. This may reflect the practise of the doctors in the two countries whom rely more on lifestyle modification instead of prescribing medications at the initial diagnosis of these conditions. Despite proven efficacy, 22 | 823 development for NASH. The lack of local data may also affect the choice of therapies.
To date, this is the largest studies on Asian biopsy-proven NAFLD patients. A combined database of anthropometric, laboratory and histological data of biopsy-proven NAFLD patients from across Asian countries such as this one will enable in-depth studies on various aspects of the disease, for example, the differences between obese and lean NASH, 27 elderly NALFD patients, 28 etc., where data on Asian patients are lacking. Despite our best effort, this study has several limitations. Firstly, histopathological examination of the liver biopsy specimens was conducted by the histopathologist of the respective centres. The slides were not reviewed again by a panel of histopathologist at a central laboratory. Nevertheless, a standardised scoring system was used and the slides were reviewed again and graded accordingly by the histopathologist of the respective centres if a different scoring system was used previously. Secondly, all the centres that participated were tertiary hospitals and patients were from specialised clinics, so the findings may not be generalisable to NAFLD patients in the general population. Thirdly, histopathological examination of liver biopsy specimen is an imperfect reference standard as it only represents 1 in 50 000 of the liver volume and is subjected to sampling variability, in addition to observer variability. 29 Nevertheless, the length of biopsy specimen and the number of portal tracts (where the data is available)
is of acceptable standard, and the histopathological examination was conducted by experienced histopathologist from the respective centres.
In conclusion, the main indication for liver biopsy across the different centres was persistently elevated serum aminotransferase levels, and a diagnosis of NASH and advanced fibrosis was seen in 62.9% and 17.2%, respectively. Older age, obesity, diabetes mellitus, dyslipidaemia, higher ALT, AST and lower platelet levels were associated with more severe liver disease. Utilisation of structured lifestyle program, vitamin E and pioglitazone was limited despite this being a cohort of biopsy-proven NAFLD patients with majority of patients having NASH. Lastly, the GO ASIA Workgroup can serve as a platform to pool clinicians and researchers with interest in NAFLD in the region to consolidate and expand the current understanding of the disease through combining and sharing of data from previous, current and future work.
